Le Lézard

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. , a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung cancer (NSCLC) ...
Stocktwits on MSN

IBRX garners retail attention on positive update in immunotherapy for lung cancer patients

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Stratifying Risk in Sarcoidosis: Laryngeal vs Nodal Management

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
Archives of Disease in Childhood

Analysis of infectious complications in paediatric autoimmune neutropenia: a French nationwide retrospective cohort study

Background Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences ...